Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters











Publication year range
1.
Clin Infect Dis ; 72(2): 315-318, 2021 01 27.
Article in English | MEDLINE | ID: mdl-33501968

ABSTRACT

Mycobacterium  genavense is a challenging opportunistic pathogen to diagnose and manage in patients with human immunodeficiency virus (HIV). Persistent immunosuppression or protracted immune reconstitution inflammatory syndrome can lead to complicated clinical courses. We describe 3 cases of M. genavense in patients with HIV representing the spectrum between disease burden and strength of immune response.


Subject(s)
HIV Infections , Immune Reconstitution Inflammatory Syndrome , Mycobacterium , HIV Infections/drug therapy , Humans , Nontuberculous Mycobacteria
3.
Clin Infect Dis ; 70(6): 1222-1225, 2020 03 03.
Article in English | MEDLINE | ID: mdl-31298273

ABSTRACT

Eight-day inpatient directly observed therapy confirmed nonadherence as the major cause of virologic failure for 9 (45%) of 20 highly treatment-experienced persons with human immunodeficiency virus, extensive antiretroviral drug resistance, and high self-reported adherence rates, preventing unnecessary regimen changes.


Subject(s)
Anti-HIV Agents , HIV Infections , HIV-1 , Anti-HIV Agents/pharmacology , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , Directly Observed Therapy , Drug Resistance, Viral , HIV Infections/drug therapy , Humans , Inpatients , Medication Adherence , Treatment Failure , Viral Load
4.
JCI Insight ; 4(8)2019 04 18.
Article in English | MEDLINE | ID: mdl-30996137

ABSTRACT

BACKGROUND: The goal of antiretroviral therapy (ART) is to suppress HIV-1 replication and reconstitute CD4+ T cells. Here, we report on HIV-infected individuals who had a paradoxical decline in CD4+ T cells despite ART-mediated suppression of plasma HIV-1 load (pVL). We defined such an immunological outcome as extreme immune decline (EXID). METHODS: EXID's clinical and immunological characteristics were compared to immunological responders (IRs), immunological nonresponders (INRs), healthy controls (HCs), and idiopathic CD4+ lymphopenia (ICL) patients. T cell immunophenotyping and assembly/activation of inflammasomes were evaluated by flow cytometry. PBMC transcriptome analysis and genetic screening for pathogenic variants were performed. Levels of cytokines/chemokines were measured by electrochemiluminescence. Luciferase immunoprecipitation system and NK-mediated antibody-dependent cellular cytotoxicity (ADCC) assays were used to identify anti-lymphocyte autoantibodies. RESULTS: EXIDs were infected with non-B HIV-1 subtypes and after 192 weeks of consistent ART-mediated pVL suppression had a median CD4+ decrease of 157 cells/µl, compared with CD4+ increases of 193 cells/µl and 427 cells/µl in INR and IR, respectively. EXID had reduced naive CD4+ T cells, but similar proportions of cycling CD4+ T cells and HLA-DR+CD38+CD8+ T cells compared with IR and INR. Levels of inflammatory cytokines were also similar in EXID and INR, but the IL-7 axis was profoundly perturbed compared with HC, IR, INR, and ICL. Genes involved in T cell and monocyte/macrophage function, autophagy, and cell migration were differentially expressed in EXID. Two of the 5 EXIDs had autoantibodies causing ADCC, while 2 different EXIDs had an increased inflammasome/caspase-1 activation despite consistently ART-suppressed pVL. CONCLUSIONS: EXID is a distinct immunological outcome compared with previously described INR. Anti-CD4+ T cell autoantibodies and aberrant inflammasome/caspase-1 activation despite suppressed HIV-1 viremia are among the mechanisms responsible for EXID.


Subject(s)
Anti-HIV Agents/therapeutic use , Autoantibodies/immunology , CD4-Positive T-Lymphocytes/immunology , HIV Infections/immunology , Lymphopenia/immunology , Adolescent , Adult , Anti-HIV Agents/pharmacology , Autoantibodies/blood , CD4 Lymphocyte Count , Female , HIV Infections/blood , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/immunology , HIV-1/isolation & purification , Humans , Immunophenotyping , Lymphopenia/blood , Male , Middle Aged , Prospective Studies , Treatment Outcome , Viral Load/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL